TKNO · Alpha Teknova
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $10.95
Note written ·
Price against the kill line
25.0% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $10.95, on record since 10 November 2026. The shares are up 13.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $10.95, 27% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 12.7
- Revenue, change on a year (%)
- +21.5
- Gross margin (%)
- 38.0
- Operating margin (%)
- −25.2
- Free cash flow, four quarters ($M)
- −6.4
- Net cash, cash less debt ($M)
- 3.3
- Enterprise value to sales (×)
- 11.2
- Free-cash-flow yield (%)
- −1.2
All filed numbers
What Alpha Teknova reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 12.7 | +21.5 | 38.0 | −25.2 |
| first filed | 12.2 | +18.5 | 40.1 | −23.7 |
| first filed | 11.1 | +13.1 | 34.2 | −38.8 |
| first filed | 10.0 | +7.8 | 32.5 | −46.2 |
| first filed | 10.5 | +9.2 | 30.7 | −38.4 |
| first filed | 10.3 | +7.0 | 38.7 | −32.9 |
| Pre-tax income ($M) | −3.5 |
| Net income ($M) four quarters: −16.0 | −3.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +0.3 |
| Operating cash flow ($M) | −5.6 |
| Capital spending ($M) | 0.8 |
| Free cash flow ($M) | −6.4 |
| Cash and short-term investments ($M) | 16.6 |
| Debt ($M) long-term debt | 13.3 |
| Net cash, cash less debt ($M) | 3.3 |
| Deferred revenue ($M) +366.7% on a year | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 5.8 |
| Inventory ($M) | 7.5 |
| Shareholders' equity ($M) | 59.8 |
| Market value ($M) | 516 |
| Enterprise value, market value plus net debt ($M) | 513 |
| Enterprise value to sales (×) | 11.2 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 8.6 |
| Free-cash-flow yield (%) | −1.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 2.6% of shares outstanding sold short, 5.8 days of average trading to cover, +0.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $144K | $0 |
The thesis
Alpha Teknova's third-quarter report on 4 November 2026 confirmed the growth case: revenue rose 22% and the company raised 2026 revenue guidance to $46-48 million. At the $8.55 close on 9 November 2026 the shares sit just below the $8.75 consensus target, so most of the good news is already priced. The next test is the 2027 revenue guidance due with full-year results in early 2027.
Teknova sells culture media, buffers and reagents to life-science, diagnostics and biotech customers, including material made to clinical-grade (GMP) standards for drug programmes. Third-quarter revenue was $12.7 million, up from $10.5 million a year earlier (company release, 4 November 2026). The growth came from the clinical side. Clinical Solutions revenue rose 86% to $3.2 million, while Lab Essentials grew 9% to $9.0 million.
The story is well known: revenue was pre-announced on 20 October 2026, the report added a $1 million lift to each end of the guidance range, and the shares had already recovered from $5.85 on 21 October 2026 to $7.86 on 28 October 2026 before it (adjusted daily closes). The report settled the question of whether guidance would hold in the company's favour. The question now is whether the clinical growth repeats, and no company event is scheduled before the 19 January 2027 insider lock-up expiry.
Bullish and bearish views on Alpha Teknova, Inc.
The bull case on Alpha Teknova, Inc. (TKNO), in brief: Clinical revenue is accelerating. The bear case: gross margin fell from the second quarter.
Bull case
- Clinical revenue is accelerating. Clinical Solutions revenue rose 86% year over year to $3.2 million in the third quarter (company release, 4 November 2026). On the 5 November 2026 call, management said custom-product demand was broad across customers and therapy types, mostly from programmes already in clinical trials.
- Guidance went up again. The company raised 2026 revenue guidance to $46-48 million from $45-47 million and reaffirmed free cash outflow below $8 million (company release, 4 November 2026). That is the second raise after the 5 August 2026 lift from $42-44 million.
- Results beat estimates. Third-quarter sales of $12.704 million beat the $11.639 million estimate, and the $0.06 loss per share beat the $0.07 estimate (Benzinga, 4 November 2026).
- Gross margin is much higher than a year ago. Third-quarter gross margin was 38.0%, against 30.7% a year earlier, and the net loss narrowed to $3.5 million from $4.3 million (company release, 4 November 2026).
- Cash burn is small and the balance sheet is rebuilt. Free cash flow was negative $1.4 million in the quarter (company release, 4 November 2026). The offering that closed on 22 October 2026 raised about $42.9 million net, on top of $16.6 million of cash and short-term investments at 30 September 2026.
- Management named a profitability threshold. The chief financial officer said on 5 November 2026 that adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) turns positive at $52-57 million of annualised revenue (MarketBeat call summary).
Bear case
- Gross margin fell from the second quarter. Gross margin slipped to 38.0% in the third quarter from 40.1% in the second (company releases, 5 August 2026 and 4 November 2026). Management guides full-year 2026 gross margin only to the mid-to-upper 30% range (call, 5 November 2026).
- Clinical orders are lumpy. The chief financial officer warned that Clinical Solutions results can swing from quarter to quarter because orders are larger (call, 5 November 2026). The chief executive said it is "still a little early" and wants another couple of quarters of evidence.
- The share count grew by 9.2 million. Underwriters exercised their full option, so the offering sold 9.2 million shares at $5.00 for $46.0 million gross (company release, 4 November 2026). Underwriters paid $4.70 a share (Form 8-K, October 2026).
- The cash may fund acquisitions. Management said it did not need the capital to reach positive cash flow and wanted flexibility, including for possible acquisitions (call, 5 November 2026). An acquisition would add execution risk to a company still losing money.
- The shares sit at the consensus target. MarketBeat's consensus target is $8.75 with a "Moderate Buy" rating (as reported 8 November 2026), against the $8.55 close on 9 November 2026. No broker raised a target after the report in coverage found to 10 November 2026; TD Cowen's $11 dates from 13 October 2026, and TD Cowen ran the offering.
- Debt is still outstanding. Borrowings were $13.2 million at 30 September 2026, and the third-quarter cash flow statement shows no long-term debt repayment (company release, 4 November 2026).
Price setup
The shares closed at $8.55 on 9 November 2026, 8.4% below the 52-week high of $9.33 (adjusted daily closes). They are up 15.7% over three months, and the 14-day relative strength index (RSI), a momentum gauge, reads 58.9. That reading sits in neutral territory and does not signal an overheated move.
The path since the offering is steep. The shares traded as low as $4.94 on 21 October 2026, closed at $5.85 that day, reached $7.86 on 28 October 2026 and $8.55 on 9 November 2026. That is a 71% rise from the 21 October 2026 close in under three weeks.
The observable crowding signs are the gap between the $5.00 offering price and the current close, a short distance to the $8.75 consensus target, and the 19 January 2027 lock-up expiry. MarketBeat showed no insider buying or selling in the three months to 28 October 2026. No company filings were made public between the 4 November 2026 report and 10 November 2026.
Catalysts ahead
- 19 January 2027: Director and executive officer lock-up from the October 2026 offering ends. First date insiders can generally sell; Form 4 filings afterwards show whether they do.
- ~5 March 2027 (est.): Fourth-quarter and full-year 2026 results with first 2027 revenue guidance. Shows whether Clinical Solutions growth repeats and whether 2027 guidance approaches the $52-57M annualised revenue management ties to positive adjusted EBITDA.
What would change the view
A daily close above $10.95, 27% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Teknova's demand comes from small and mid-sized biotechs and their contract manufacturers, which management named as the source of custom-product growth (company release, 4 November 2026). The shares therefore tend to move with biotech funding conditions and small-cap life-science tools sentiment more than with the broad index. Larger tools suppliers' results feed the same reading: Thermo Fisher beat estimates and raised guidance on 21 October 2026 (Benzinga). Teknova's small size means company-specific news, such as its October equity sale, can outweigh sector moves on any given day.
The evidence, claim by claim (8)
- Q3 2026 revenue $12.7M, up 22% from $10.5M; Lab Essentials $9.0M (+9%), Clinical Solutions $3.2M (+86%). Teknova Q3 2026 results press release · as of
- Q3 2026 gross margin 38.0% versus 30.7% a year earlier and 40.1% in Q2 2026; net loss $3.5M ($0.06 per share) versus $4.3M ($0.08). Teknova Q3 2026 results press release · as of
- 2026 revenue guidance raised to $46-48M from $45-47M; free cash outflow guidance of less than $8M reaffirmed. Teknova Q3 2026 results press release · as of
- Offering closed with 9.2M shares sold at $5.00, including the underwriters' full option; gross proceeds $46.0M, net about $42.9M. Teknova Q3 2026 results press release · as of
- Cash and short-term investments $16.6M and total borrowings $13.2M; Q3 free cash flow negative $1.4M. Teknova Q3 2026 results press release · as of
- CFO said adjusted EBITDA turns positive at $52-57M annualised revenue; full-year 2026 gross margin expected in the mid-to-upper 30% range; 2027 guidance comes with full-year results. Q3 2026 earnings call (MarketBeat summary) · as of
- Q3 sales of $12.704M beat the $11.639M estimate; loss of $0.06 per share beat the $0.07 estimate. Benzinga · as of
- Consensus rating Moderate Buy with a consensus target of $8.75. MarketBeat data via The Cerbat Gem · as of
Sources
- Teknova Reports Third Quarter 2026 Financial Results · globenewswire.com ·
- Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year · finviz.com ·
- MarketBeat ·
- Alpha Teknova Q3 Earnings Call Highlights · thecerbatgem.com ·
- Alpha Teknova, Inc. (TKNO) Stock Price, News, Quote & History · finance.yahoo.com
Related · shared themes
DHR
Danaher
Danaher's shares have a modest edge over the S&P 500 because mid-teens bioprocessing orders should reach revenue in 2027. Formal 2027…
ICLR
ICON
ICON plc's orders have recovered into fee-earning work, with a third-quarter direct-fee book-to-bill near 1.3, giving the shares a modest…
IQV
IQVIA Holdings
IQVIA's clinical-research bookings are outpacing revenue, with third-quarter 2026 bookings up 15% at a 1.2x book-to-bill and guidance…
LH
Labcorp Holdings
Labcorp's 11.5% Central Labs growth and raised 2026 guidance make its shares modestly more likely to beat the S&P 500 over three months.…
See also · stocks to watch